Non-informative “profiles” [General Sta­tis­tics]

posted by Helmut Homepage – Vienna, Austria, 2014-03-11 18:22 (4478 d 00:20 ago) – Posting: # 12600
Views: 11,658

Hi Fabrice,

❝ The context is the following:

❝ – Phase IIa multiple-dose placebo-controlled study, so only one active treatment

❝ – Oral inhalation, resulting in quite high inter- and intra-patient PK variability


This was one of the possibilities I suspected. ;-) Let’s see whether our specialist for OIPs (ElMaestro) will join the party…

❝ The study is thus not at risk :cool: from a PK point of view.

❝ But I was nevertheless interested on what would be the suggestions to best handle such a situation from a pure statistical point of view.


OK, I think cards are stacked against you if you want to stick to NCA only. PK modeling (or even PopPK/PD if you are courageous) with censored data might be helpful if you face a lot of missing data.

❝ For PK, the potential impact is on the steady-state vs single dose comparison, but you can also simply consider the computation of the descriptive geometric mean Cmax and AUC... how to best deal with a zero value?


Too bad that ln(0) is undefined…

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
113 visitors (0 registered, 113 guests [including 16 identified bots]).
Forum time: 19:43 CEST (Europe/Vienna)

I have never in my life learned anything
from any man who agreed with me.    Dudley Field Malone

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5